Literature DB >> 20826833

Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project.

Dorthe Johansen1, Tanja Stocks, Håkan Jonsson, Björn Lindkvist, Tone Björge, Hans Concin, Martin Almquist, Christel Häggström, Anders Engeland, Hanno Ulmer, Göran Hallmans, Randi Selmer, Gabriele Nagel, Steinar Tretli, Pär Stattin, Jonas Manjer.   

Abstract

BACKGROUND: The aim of this study was to investigate the association between factors in metabolic syndrome (MetS; single and combined) and the risk of pancreatic cancer.
METHODS: The Metabolic Syndrome and Cancer Project is a pooled cohort containing data on body mass index, blood pressure, and blood levels of glucose, cholesterol, and triglycerides. During follow-up, 862 individuals were diagnosed with pancreatic cancer. Cox proportional hazards analysis was used to calculate relative risks (RR) with 95% confidence intervals using the above-mentioned factors categorized into quintiles and transformed into z-scores. All z-scores were summarized and a second z-transformation creating a composite z-score for MetS was done. All risk estimates were calibrated to correct for a regression dilution bias.
RESULTS: The trend over quintiles was positively associated with the risk of pancreatic cancer for mid-blood pressure (mid-BP) and glucose in men and for body mass index, mid-BP, and glucose in women. The z-score for the adjusted mid-BP (RR, 1.10; 1.01-1.20) and the calibrated z-score for glucose (RR, 1.37; 1.14-1.34) were positively associated with pancreatic cancer in men. In women, a positive association was found for calibrated z-scores for mid-BP (RR, 1.34; 1.08-1.66), for the calibrated z-score for glucose (RR, 1.98; 1.41-2.76), and for the composite z-score for MetS (RR, 1.58; 1.34-1.87).
CONCLUSION: Our study adds further evidence to a possible link between abnormal glucose metabolism and risk of pancreatic cancer. IMPACT: To our knowledge, this is the first study on MetS and pancreatic cancer using prediagnostic measurements of the examined factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826833     DOI: 10.1158/1055-9965.EPI-10-0234

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

Review 1.  Association of cholesterol with risk of pancreatic cancer: a meta-analysis.

Authors:  Jia Wang; Wei-Jing Wang; Long Zhai; Dong-Feng Zhang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 2.  Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer.

Authors:  Guido Eibl; Zobeida Cruz-Monserrate; Murray Korc; Maxim S Petrov; Mark O Goodarzi; William E Fisher; Aida Habtezion; Aurelia Lugea; Stephen J Pandol; Phil A Hart; Dana K Andersen
Journal:  J Acad Nutr Diet       Date:  2017-09-12       Impact factor: 4.910

Review 3.  The complexities of obesity and diabetes with the development and progression of pancreatic cancer.

Authors:  Bin Bao; Zhiwei Wang; Yiwei Li; Dejuan Kong; Shadan Ali; Sanjeev Banerjee; Aamir Ahmad; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-12-01

4.  [Diabetes mellitus as a prognostic marker in oropharyngeal and laryngeal squamous cell carcinoma].

Authors:  K Zaoui; J Doll; P Stiebi; P Federspil; P K Plinkert; J Hess
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

5.  Coffee, tea, and sugar-sweetened carbonated soft drink intake and pancreatic cancer risk: a pooled analysis of 14 cohort studies.

Authors:  Jeanine M Genkinger; Ruifeng Li; Donna Spiegelman; Kristin E Anderson; Demetrius Albanes; Leif Bergkvist; Leslie Bernstein; Amanda Black; Piet A van den Brandt; Dallas R English; Jo L Freudenheim; Charles S Fuchs; Graham G Giles; Edward Giovannucci; R Alexandra Goldbohm; Pamela L Horn-Ross; Eric J Jacobs; Anita Koushik; Satu Männistö; James R Marshall; Anthony B Miller; Alpa V Patel; Kim Robien; Thomas E Rohan; Catherine Schairer; Rachael Stolzenberg-Solomon; Alicja Wolk; Regina G Ziegler; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-22       Impact factor: 4.254

6.  p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.

Authors:  Carolina Torres; Georgina Mancinelli; Jose Cordoba-Chacon; Navin Viswakarma; Karla Castellanos; Sam Grimaldo; Sandeep Kumar; Daniel Principe; Matthew J Dorman; Ronald McKinney; Emilio Hirsch; David Dawson; Hidayatullah G Munshi; Ajay Rana; Paul J Grippo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-02       Impact factor: 11.205

7.  Association of Barrett's esophagus with type II Diabetes Mellitus: results from a large population-based case-control study.

Authors:  Prasad G Iyer; Bijan J Borah; Herbert C Heien; Ananya Das; Gregory S Cooper; Amitabh Chak
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-13       Impact factor: 11.382

8.  Making the most of the imaging we have: using head MRI to estimate body composition.

Authors:  C M Lack; G J Lesser; U N Umesi; J Bowns; M Y Chen; D Case; R C Hightower; A J Johnson
Journal:  Clin Radiol       Date:  2016-01-12       Impact factor: 2.350

Review 9.  Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies.

Authors:  J M Genkinger; C M Kitahara; L Bernstein; A Berrington de Gonzalez; M Brotzman; J W Elena; G G Giles; P Hartge; P N Singh; R Z Stolzenberg-Solomon; E Weiderpass; H-O Adami; K E Anderson; L E Beane-Freeman; J E Buring; G E Fraser; C S Fuchs; S M Gapstur; J M Gaziano; K J Helzlsouer; J V Lacey; M S Linet; J J Liu; Y Park; U Peters; M P Purdue; K Robien; C Schairer; H D Sesso; K Visvanathan; E White; A Wolk; B M Wolpin; A Zeleniuch-Jacquotte; E J Jacobs
Journal:  Ann Oncol       Date:  2015-09-07       Impact factor: 32.976

Review 10.  Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss.

Authors:  Mu Xu; Xiaoman Jung; O Joe Hines; Guido Eibl; Yijun Chen
Journal:  Pancreas       Date:  2018-02       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.